drugset
drugset / Trial / NCT00532285

Primary Paclitaxel Plus Gemcitabine in Patients With Stage II and III Breast Cancer

NCT00532285 ↗

Phase 2 Terminated 44 enrolled National Cancer Center, Korea
Non-randomizedSingle-groupOpen-labelTreatment

Summary

This is an open labeled phase II single arm trial. The patients with clinical stage II and III will undergo core-needle biopsy of breast tumor for histologic diagnosis, immunohistochemical studies for estrogen receptor (ER), progesterone receptor(PR), HER-2/neu and others. PET or ultrasound results will determine the positivity of lymph node metastasis.

Timeline

Start
2005-09
Primary completion
2006-04
Completion
2009-08

Outcome

Outcome not reported

Stopped: “terminated”

Drugs

EvaluationDrugModalityDoseRoute
Subject Gemcitabine Small molecule 1200 mg/m2 Intravenous
Subject Paclitaxel Small molecule 80 mg/m2 Intravenous

Indications

breast cancer